Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[ω-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 6855-6869

  Smid, Pieter ^a   Coolen, Hein K A C ^a   Keizer, Hiskias G ^a   Van Hes, Rolf ^a   De Moes, Jan Peter ^a   Den Hartog, Arnold P ^a   Stork, Bob ^a   Plekkenpol, Rob H ^a   Niemann, Leonarda C ^a   Stroomer, Cees N J ^a   Tulp, Martin Th M ^a   Van Stuivenberg, Herman H ^a   McCreary, Andrew C ^a   Hesselink, Mayke B ^a   Herremans, Arnoud H J ^a   Kruse, Chris G ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 [3 (5 FLUORO 1H INDOL 3 YL)PROPYL] 1 PIPERAZINYL] 2 METHYL 1,4 BENZOXAZIN 3(4H) ONE; 8 [4 [3 (5 FLUORO 1H INDOL 3YL)PROPYL]PIPERAZIN 1 YL] 4H BENZO[1,4]OXAZIN 2 METHYL 3 ONE; BICYCLO COMPOUND; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CLIMBING; CONFORMATIONAL TRANSITION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EVALUATION; HUMAN; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; PHARMACOPHORE; PSYCHOSIS; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOXAZINES; BIOLOGICAL TRANSPORT; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; INDOLES; MALE; MODELS, MOLECULAR; P-GLYCOPROTEIN; PIPERAZINES; RATS; RECEPTORS, DOPAMINE D2; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27444437203     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050148z     Document Type: Article

References (49)

1. Meltzer, H. Y.; McGurk, S. R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999, 25, 233-255.
2. Keck, P. E.; Strakowski, S. M.; McCelroy, S. L. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J. Clin. Psychiatry 2000, 61, 4-9.
3. (b) Siris, S. G. Depression in schizophrenia: Perspective in the era of 'atypical' antipsychotic agents. Am. J. Psychiatry 2000, 157, 1379-1389.
4. Birchwood, M.; Mason, R.; Macmillan, F. Depression, demoralization and control over psychotic illness: A comparison of depressed and nondepressed patients with a chronic psychosis. Psychol Med. 1993, 23, 387-395.
5. (b) Roy, A.; Thompson, R.; Kennedy, S. Depression in chronic schizophrenia. Br. J. Psychiatry 1983, 142, 465-470.
6. 3H]spiroperidol binding sites in rat striatum: Evidence for pharmacologically distinct classes of receptors. Brain Res. 1982, 235, 205-211.
7. 2-dopaminergic receptors. Jpn. J. Pharmacol. 1983, 33, 749-755.
8. (c) Johnstone, E. C.; Crow, T. J.; Frith, C. D.; Carney, M. W.; Price, J. S. Mechanism of the anti-psychotic effect in the treatment of acute schizophrenia. Lancet 1978, 8069, 848-851.
9. (d) Peroutka, S. J.; Snyder, S. H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiatry 1980, 137, 1518-1522.
10. Creese, I.; Burt, D. R.; Snyder, S. H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192, 481-483.
11. (b) Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261, 717-719.
12. Goldberg, T. E.; Greenberg, R. D.; Griffin, S. J.; Gold, J. M.; Kleinman, J. E.; Pickar, D.; Schultz, S. C.; Weinberger, D. R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry 1993, 162, 43-48.
13. Meltzer, H. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999, 21, 106S-115S.
14. Silver, H.; Barash, I.; Aharon, N.; Kaplan, A.; Poyurovsky, M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic Schizophrenic patients: A placebo-controlled study. Int. Clin. Psychopharmacol. 2000, 15, 257-261.
15. Spina, E.; De Dominico, P.; Ruello, C.; Longobardo, N.; Gitto, C.; Ancione, M.; Di Rosa, A. E.; Caputi, A. P. Adjunctive fluoxetine in the treatment of negative symptoms in chronic Schizophrenic patients. Int. Clin. Psychopharmacol. 1994, 9, 281-285.
16. (b) Goff, D. C.; Midha, K. K.; Sarid-Segal, O.; Hubbard, J. W.; Amico, E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995, 117, 417-423.
17. (c) Buchanan, R. W.; Kirkpatrick, B.; Bryant, N.; Ball, P.; Breier, A. Fluoxetine augementation of clozapine treatment in patients with schizophrenia. Am. J. Psychiatry 1996, 153, 1625-1627.
18. Taiminen, T. J.; Syvalahti, E.; Saarijarvi, S.; Niemi, H.; Lehto, H.; Ahola, V.; Salokangas, R. K. Citalopram as adjuvant in schizphrenia: Further evidence for a serotonergic dimension in schizophrenia. Int. Clin. Psychopharmacol. 1997, 12, 31-35.
19. (b) Salokangas, R. K.; Saarijarvi, S.; Taiminen, T.; Kallioniemi, H.; Niemi, H.; Tuominen, J.; Ahola, V.; Syvalahti, E. Citalopram as an adjuvant in chronic schizophrenia: A double-blind placebo-controlled study. Acta Psychiatr. Scand. 1996, 94, 175-180.
20. Silver, H.; Shmugliakov, N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated Schizophrenia: Evidence for a specific serotonergic effect from a double-blind study. J. Clin. Psychopharmacol. 1998, 18, 208-211.
21. Centorrino, F.; Baldessarini, R. J.; Frankenburg, F. R.; Kando, J.; Volpicelli, S. A.; Flodd, J. G. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am. J. Psychiatry 1996, 153, 820-822.
22. 2 receptor antagonism with serotonin reuptake inhibition. Bioorg. Med. Chem. Lett. 2003, 13, 405-408.
23. Hartog, J.; Olivier, B.; van Wijngaarden, I.; Kruse, C. G.; van der Heijden, J. A. M.; van Dalen-van der As, D. A. New pharmaceutical compositions having a psychtropic activity. Patent EP0189612, 1985.
24. 2 receptor and serotonin 5HT1A receptor affinities. Bioorg. Med. Chem. Lett. 2001, 11, 2345-2349.
25. Compounds 6, m = 2 and m = 3, are commercially available. Compound 6, m = 4, can be prepared as described in Frits, H. E. J. Org. Chem, 1963, 28, 1384-1386.
26. Anderson, N. G.; Winter, W. J.; et al. Process development of 5-fluoro-3-[3-[4-(5-methoxy-4pyrimidinyl)-1-piperazinyl]propyl] -1H-indole-dihydrochloride. Org. Process Res. Dev. 1997, 1, 300-210.
27. Mewshaw, R. E.; Husbands, M.; Gildersleeve, E. S.; Webb, M. B.; Shi, X.; Mazandarani, H.; Cockett, M. I.; Ochalski, R.; Brennan, J.; Abou-Gharbia, M.; Marquis, K.; McGaughey, G. B.; Coupet, J.; Andree, T. H. New generation dopaminergic agents.2. Discovery of 3-OH-phenoxyethylamine and 3-OH-N1-phenylpiperazine dopaminergic templates. Bioorg. Med. Chem. Lett. 1998, 8, 295-300.
28. Huffman, C. W. Formylation of amines. J. Org. Chem. 1958, 23, 727-729.
29. 1A adrenoreceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia. J. Med. Chem. 2001, 44, 1971-1985.
30. Lee, B. S.; Chu, S.; Lee, I. Y.; Lee, B.-S.; EuiSong, C.; Chi, D. Y. Beckmann rearrangement of 1-indanone oxim derivatives using aluminium chloride and mechanistic considerations. Bull. Korean Chem. Soc. 2000, 21 (9), 860-866.
31. Tomita, M.; Minami, S.; Uyeo, S. The Schmidt reaction with benzocycloalkenones. J. Chem. Soc. (C) 1969, 183-189.
32. Van Hes, R.; Van der Heijden, J. A. M.; Kruse, C. G.; Tipker, J.; Tulp, M. T. M.; Visser, G. M.; Van Vliet, B. J. New phenylpiperazines. Patent WO01/14330, 2001.
33. Graandy, D. K.; Marchionni, M. A., Makam, H.; Stofko, R. E.; Alfano, M.; Frothingham, L.; Fischer, J. B.; Burke-Howie, K. J.; Bunzow, J. R.; Server, A. C.; Civelli, O. Cloning of cDNA and gene for a human D-2 dopamine receptor. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 9762-9766.
34. Habert, E.; Graham, D.; Tahraoui, L.; Claustre, Y.; Langer, S. Z. Characterisation of [3H]-paroxetine binding to rat cortical membranes. Eur. J. Pharmacol. 1985, 118, 107-114.
35. i = 0.2 nM).
36. Costall, B.; Naylor, R. J.; Nohria, V. Climbing behaviour induced by apomorphine in mice: A potential model for the detection of neuroleptic activity. Eur. J. Pharmacol. 1978, 1, 39-50.
37. Jacobs, B. L. An animal behavior model for studying central serotonergic synapses. Life Sci. 1976, 19 (6), 777-785.
38. 3 receptor ligands. J. Med. Chem. 2003, 46, 3883-3899.
39. Bureau, R.; Daveu, C.; Lancelot, J.-C.; Rault, S. Molecular design based on 3D-pharmacophore. Application on 5-HT subtypes receptors. J. Chem. Inf. Comput. Sci. 2002, 42, 429-436.
40. Tipker, J. Internal communication, unpublished results.
41. Dijkstra, G. D. H. Conformational analysis of 1-arylpiperazines and 4-arylpiperidines. Recl. Trav. Chim. Pays-Bas 1993, 112, 151-160.
42. 1A receptor ligands. J. Med. Chem. 1995, 38, 1942-1954.
43. The lowest energy conformation that was found had an h.o.f. of 11.4 kcal/mol.
44. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discuss. Today 2004, 9, 641-651.
45. Schinkel, A. H.; Wagenaar, E.; Mol, C. A. A. M.; van Deemter, L. P-Glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97 (11), 2517-2524.
46. (b) Schinkel, A. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A. A. M.; Borst, P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J. Clin. Invest. 1995, 96, 1698-1705.
47. Van der Heijden, J. A. M.; Bradford, D. Behav. Brain Res. 1988, 31, 61-69.
48. 2 receptor in CHO cells). A pharmacological paper with more details on the in vitro and in vivo pharmacology of 45c is in preparation.
49. Tripos Inc., St. Louis, MO 63144.